|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The circulating non-coding RNA landscape for biomarker research: lessons and prospectsfrom cardiovascular diseases显示文摘人的染色体的弥漫的抄写为无数非编码的 RNA 分子(ncRNAs ) 的生产负责有规章的功能的他们的一些。在心血管的生物学的 ncRNAs 的枢轴的角色在最后十年被揭开了,从在心血管的开发和功能的 micro-RNAs 的参与的描述开始,并且作为心血管的疾病的 biomarkers 由传播 ncRNAs 的使用列在后面。人的非编码的 secretome 被几 RNA 种填写在身体液体传播并且能为诊断和结果预言被用作 biomarkers。在心血管的疾病,分泌了 ncRNAs 包括心肌的梗塞,心脏的失败,和 atrial 纤维性颤动被描述了为几个条件的 biomarkers。在传播之中, ncRNAs, micro-RNAs (miRNAs ) ,长 noncoding RNA (lncRNAs ) 和圆形的 RNA (circRNAs ) 在不同心血管的疾病作为 biomarkers 被建议了。与标准 biomarkers 比较, ncRNAs 的生物化学的性质为更好的稳定性和灵活存储提供样品,和增加的敏感和特性的条件。在这评论,我们把当前的趋势和 ncRNA secretome 部件的使用的未来前景描述为心血管的疾病的 biomarkers,包括与他们的分泌物机制和规章的行动联系的开的问题。 | Ewa STFPIEN Marina C COSTA Szczepan KURC Anna DROZDZ Nuno CORTEZ-DIAS Francisco J ENGUITA | 2018 | Acta Pharmacologica Sinica2018，39，7： | 14 |
| 2 | 帕博利珠单抗联合以铂类为基础的化疗治疗非小细胞肺癌合并稳定性脑转移患者的结局:KEYNOTE-021、-189和-407研究的汇总分析显示文摘背景与目的此项探索性分析回顾评价了晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的结局,旨在确定基线时合并脑转移是否会影响一线应用帕博利珠单抗联合化疗(pembrolizumab plus chemotherapy,PC)比对单用化疗的疗效。患者和方法对KEYNOTE-021队列G(非鳞癌)、KEYNOTE-189(非鳞癌)和KEYNOTE-407(鳞癌)三项研究晚期NSCLC患者的数据进行汇总分析。患者接受含铂两药化疗和/或35个周期帕博利珠单抗治疗(每3周200 mg)。所有研究均纳入了经治或初治的稳定性脑转移患者(KEYNOTE-189与KEYNOTE-407研究纳入初治脑转移患者)。经治的脑转移患者已处于病情稳定的状态≥2周(KEYNOTE-021队列G患者≥4周),无新发或脑转移病灶扩大的证据且入组前至少3天以上未使用激素。初治的无症状脑转移患者需定期接受脑部影像学检查。结果共纳入1298例患者,其中171例有基线脑转移,1127例无脑转移。两组的中位随访时间(范围)在数据截止时分别为10.9(0.1-35.1)个月和11.0(0.1-34.9)个月。合并脑转移和无脑转移患者的总生存期[0.48(95%CI:0.32-0.70)和0.63(95%CI:0.53-0.75)]和无进展生存期[0.44(95%CI:0.31-0.62)和0.55(95%CI:0.48-0.63)]的风险比(PC/化疗)相似。合并脑转移的患者中,PC组和单用化疗组患者的中位总生存期分别为18.8个月和7.6个月,中位无进展生存期分别为6.9个月和4.1个月。无论是否合并脑转移,PC组患者的客观缓解率都高于单用化疗组,且缓解持续时间有显著延长。合并脑转移的患者中,PC组与单用化疗组的治疗相关不良事件发生率分别为88.2%和82.8%;而无脑转移的患者中,两组治疗相关不良事件的发生率分别为94.5%和90.6%。结论无论是否合并脑转移,与单用化疗相比,帕博利珠单抗联合以铂类为基础的组织学特异性化疗可改善所有PD-L1亚组的临床结局,其中包括PD-L1肿瘤比例评分<1%的患者,并且在晚期NSCLC患者中安全性良好。该方案是晚期NSCLC初治患者的标准方案,并可用于合并稳定性脑转移的患者。 | 周清(翻译校对) Steven F Powell Delvys Rodríguez-Abreu Corey J Langer Ali Tafreshi Luis Paz-Ares Hans-Georg Kopp Jeronimo Rodríguez-Cid Dariusz M Kowalski Ying Cheng Takayasu Kurata Mark M Awad Jinaxin Lin Bin Zhao M Catherine Pietanza Bilal Piperdi Marina C Garassino | 2022 | 中国肺癌杂志2022，25，1： | 6 |
| 3 | Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis via AMPK and mTOR regulation显示文摘BACKGROUND Arachidyl amido cholanoic acid(Aramchol)is a potent downregulator of hepatic stearoyl-CoA desaturase 1(SCD1)protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis.In a phase IIb clinical trial in patients with nonalcoholic steatohepatitis(NASH),52 wk of treatment with Aramchol reduced blood levels of glycated hemoglobin A1c,an indicator of glycemic control.AIM To assess lipid and glucose metabolism in mouse hepatocytes and in a NASH mouse model[induced with a 0.1%methionine and choline deficient diet(0.1MCD)]after treatment with Aramchol.METHODS Isolated primary mouse hepatocytes were incubated with 20μmol/L Aramchol or vehicle for 48 h.Subsequently,analyses were performed including Western blot,proteomics by mass spectrometry,and fluxomic analysis with 13C-uniformly labeled glucose.For the in vivo part of the study,male C57BL/6J mice were randomly fed a control or 0.1MCD for 4 wk and received 1 or 5 mg/kg/d Aramchol or vehicle by intragastric gavage for the last 2 wk.Liver metabolomics were assessed using ultra-high-performance liquid chromatography-time of flight-MS for the determination of glucose metabolism-related metabolites.RESULTS Combination of proteomics and Western blot analyses showed increased AMPK activity while the activity of nutrient sensor mTORC1 was decreased by Aramchol in hepatocytes.This translated into changes in the content of their downstream targets including proteins involved in fatty acid(FA)synthesis and oxidation[PACCα/β(S79),SCD1,CPT1A/B,HADHA,and HADHB],oxidative phosphorylation(NDUFA9,NDUFB11,NDUFS1,NDUFV1,ETFDH,and UQCRC2),tricarboxylic acid(TCA)cycle(MDH2,SUCLA2,and SUCLG2),and ribosome(P-p70S6K[T389]and P-S6[S235/S236]).Flux experiments with 13Cuniformely labeled glucose showed that TCA cycle cataplerosis was reduced by Aramchol in hepatocytes,as indicated by the increase in the number of rounds that malate remained in the TCA cycle.Finally,liver metabolomic analysis showed that glucose homeostasis was improved by Aramchol in 0.1MCD fed mice in a dose-dependent manner,showing normalization of glucose,G6P,F6P,UDP-glucose,and Rbl5P/Xyl5P.CONCLUSION Aramchol exerts its effect on glucose and lipid metabolism in NASH through activation of AMPK and inhibition of mTORC1,which in turn activate FAβ-oxidation and oxidative phosphorylation. | David Fernández-Ramos Fernando Lopitz-Otsoa Laura Delacruz-Villar Jon Bilbao Martina Pagano Laura Mosca Maider Bizkarguenaga Marina Serrano-Macia Mikel Azkargorta Marta Iruarrizaga-Lejarreta Jesús Sot Darya Tsvirkun Sebastiaan Martijn van Liempd Felix M Goni Cristina Alonso María Luz Martínez-Chantar Felix Elortza Liat Hayardeny Shelly C Lu JoséM Mato | 2020 | World Journal of Gastroenterology2020，26，34： | 5 |
| 4 | Toxicological effects of dietary bio- genic amines显示文摘 | Victor L Marina C Maria F | 2010 | Current Nutrition & Food Science2010，6，2： | 1 |
| 5 | Synthesis, characterization and photocatalytic activity of different metal-dopedtitania systems 显示文摘 | Colmenares J C Aramendia M A Marinas A | 2006 | Applied Catalysis a-General2006，306，： | 1 |
| 6 | Comparison of two analytical methods for the determination of organotin compounds in marine organisms显示文摘 | CAMILLA L MARINA D C EMANUELE M | 2009 | Comptes Rendus Chirnie2009，12，8： | 1 |
| 7 | Recent advances in the analysis of antibiotics by capillary electrophoresis显示文摘 | GARCIA-RUIZ C MARINA M L | 2006 | Electrophoresis2006，27，1： | 1 |
| 8 | Study of canine parvovirus evolution: comparative analysis of full-length VP2 gene sequences from Argentina and international field strains 显示文摘 | Marina G C Maximiliano W Lorena B | 2012 | Virus Genes2012，44，： | 1 |
| 9 | Virgin coconut oi1:emerging functional food oil显示文摘 | Marina A M Man Y B C Amin I | 2009 | Trends in Food Science&Technology2009，20，10： | 1 |
| 10 | Rapid detection of the addition of soybean proteins to cheese and other dairy products by reversed-phase peffusion chromatography显示文摘 | GARCIA M C MARINA M L | 2006 | Food Addit Contain2006，23，4： | 1 |
| 11 | Influence of carbohydrates on the stability and structure of a hyperglycosylated human interferon alpha mutein显示文摘 | Natalia C Marina E Ricardo K | 2010 | Biochimie2010，92，： | 1 |
| 12 | Analysis of bovine whey protein in soybean dairy-like products by capillary electrophoresis显示文摘 | Garcia-Ruiz C Torre M Marina M L | 1999 | J Chromatogr A1999，，859： | 1 |
| 13 | Accuracy of stereotactic localisation with magnetic resonance compared to CT scan: experimental findings 显示文摘 | Landi A Marina R DeGrandi C | 2001 | Acta Neurochir2001，143，： | 1 |
| 14 | Identification of native angiotensin-I converting enzyme inhibitory peptides in commercial soybean based infant formulas using HPLC-Q-ToF- MS 显示文摘 | PUCHALSKA P GARCLA M C MARINA M L | 2014 | Food Chemistry2014，157，： | 1 |
| 15 | Macrophage reverse cholesterol transport key to the regression of atherosclerosis显示文摘 | Marina C Daniel J R | | 0，，21： | 1 |
| 16 | erm(B)-Carrying Elements in Tetracycline-Resistant Pneumococci and Correspondence between Tn1545 and Tn6003显示文摘 | Ileana C Emily T Marina M | 2008 | Antimicrob Agents Chemother2008，52，4： | 1 |
| 17 | Microporous membrane filters:Astatic light scattering study显示文摘 | LUCA C MARINA C | 1997 | Physical A1997，235，： | 1 |
| 18 | A solid oxide fuel cell with a gadolinia-doped ceria anode: preparation and performance显示文摘 | Marina O A Bagger C Primdahl S | 1999 | Solid State Ionics1999，123，： | 1 |
| 19 | Solid Oxide Fuel Cell with Gadolinia-doped Ceria Anode: Preparation and Performance显示文摘 | Bagger C Primdahl S | 1999 | SolidS tate Ionics1999，123，： | 1 |
| 20 | High prevalence of 1762T 1764A mutations in the basic core promoter of hepatitis B virus isolated from black africans with hepatocellular carcinoma compared with asymptomatic carriers 显示文摘 | Marina B Anna K Michael C K | 1999 | Hepatology1999，29，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员